Review of economic evidence on the impact of substandard and falsified medicines in low and middle-income countries
- In: Oral presentation on Tuesday, 12 September 2017, 14:30-17:30
- At: Seoul (South Korea) (2017)
- Type: Presentation
- By: YEMEKE, Tatenda (United States)
- Co-author(s): Sachiko Ozawa
Five databases (PubMed, EconLit, Global Health, EMBASE and SCOPUS) were searched for articles containing data on prevalence and/or economic impact of SF medicines in LMICs. Studies that did not seek to quantify the problem or that pertained only to high-income countries were excluded. Data describing setting, medicine, disease target,.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019